Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
Funding Rounds (3) - $149.33MUpdate
Board Members and Advisors (4)Update
Padualaan 8 (postvak 133)
Utrecht, 3584 CH